文献速递慢性肾脏病遗传性与小管间质肾病

常染色体显性多囊肾病随机试验结局的范围与变异性:系统综述

Range and Variability of Outcomes Reported in Randomized Trials Conducted in Patients With Polycystic Kidney Disease: A Systematic Review.
PubMed 文献 · Am J Kidney Dis · 2020-03-11

该系统综述纳入68项成人ADPKD随机试验,共报告1413种不同结局指标,归为97个域。替代终点域报告最多,患者报告结局较少;结局范围广且异质性高,亟需建立核心结局集。

要点

  • ADPKD试验报告1413种结局指标,归为97个域,异质性高。
  • 最常报告域为肾功能(79%试验)、肾脏和囊肿体积(63%)、血压(40%)。
  • 患者报告结局报告较少,需共识核心结局集。

核心结论

  • ADPKD试验结局范围广且高度可变,替代结局最常报告,患者报告结局不常见,需建立核心结局集。

研究设计与样本

  • 系统综述纳入68项成人ADPKD随机试验,提取所有离散结局指标并归为97个域。

主要发现

  • 68项试验共报告1413种不同结局指标,97个域中替代域41个(42%)、临床域30个(31%)、患者报告域26个(27%)。
  • 替代域中最常报告:肾功能(54项;79%试验;46种指标)、肾脏和囊肿体积(43项;63%试验;52种指标)、血压(27项;40%试验;30种指标)。
  • 临床域中最常报告:感染(10项;15%;21种指标)、心血管事件(9项;13%;6种指标)、需要肾脏替代治疗的肾衰竭(8项;12%;5种指标)。
  • 患者报告域中最常报告:ADPKD相关疼痛(16项;24%;26种指标)、其他原因疼痛(11项;16%;11种指标)、腹泻/便秘/胀气(10项;15%;9种指标)。

临床怎么用

  • 解读ADPKD试验时应关注结局指标异质性,替代终点与患者报告结局需分别评估。
  • 未来ADPKD试验设计可参考核心结局集需求,优先纳入对患者和临床医生有意义的结局。

局限性

  • 仅对每个类别中报告最多的3个域进行结局指标详细分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Trials in autosomal dominant polycystic kidney disease (ADPKD) have increased, but their impact on decision making has been limited. Because heterogeneity in reported outcomes may be responsible, we assessed their range and variability in ADPKD trials. STUDY DESIGN: Systematic review. SETTING & STUDY POPULATION: Adult participants in clinical trials in ADPKD. SELECTION CRITERIA FOR STUDIES: We included trials that studied adults and were published in English. For trials that enrolled patients without ADPKD, only those enrolling ≥50% of participants with ADPKD were included. DATA EXTRACTION: We extracted information on all discrete outcome measures, grouped them into 97 domains, and classified them into clinical, surrogate, and patient-reported categories. For each category, we choose the 3 most frequently reported domains and performed a detailed analysis of outcome measures. ANALYTICAL APPROACH: Frequencies and characteristics of outcome measures were described. RESULTS: Among 68 trials, 1,413 different outcome measures were reported. 97 domains were identified; 41 (42%) were surrogate, 30 (31%) were clinical, and 26 (27%) were patient reported. The 3 most frequently reported domains were in the surrogate category: kidney function (54; 79% of trials; using 46 measures), kidney and cyst volumes (43; 63% of trials; 52 measures), and blood pressure (27; 40% of trials, 30 measures); in the clinical category: infection (10; 15%; 21 measures), cardiovascular events (9; 13%; 6 measures), and kidney failure requiring kidney replacement therapy (8; 12%; 5 measures); and in the patient-reported category: pain related to ADPKD (16; 24%; 26 measures), pain for other reasons (11; 16%; 11 measures), and diarrhea/constipation/gas (10; 15%; 9 measures). LIMITATIONS: Outcome measures were assessed for only the top 3 domains in each category. CONCLUSIONS: The outcomes in ADPKD trials are broad in scope and highly variable. Surrogate outcomes were most frequently reported. Patient-reported outcomes were uncommon. A consensus-based set of core outcomes meaningful to patients and clinicians is needed for future ADPKD trials.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Sautenet B, Cho Y, Gutman T, et al. Range and Variability of Outcomes Reported in Randomized Trials Conducted in Patients With Polycystic Kidney Disease: A Systematic Review. Am J Kidney Dis. 2020. PMID: 32171640. doi:10.1053/j.ajkd.2019.12.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。